Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well toleratedRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024 First clinical data updates for Immatics’ next-generation TCR Bispecifics, TCER® IMA401 (MAGEA4/8) and TCER® IMA402 (PRAME), from ongoing Phase 1 dose escalation trials planned for 2H 2024; updates to include details on safety, pharmacokinetics and initial anti-tumor activity In May 2023, Bristol Myers Squibb exercised first opt-in into the autologous cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment in July 2023 In September 2023, Immatics and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics; Immatics received $120 million upfront payment, and the total deal volume could exceed $1.7 billion$201.5 million public offering completed on January 22, 2024Cash and cash equivalents as well as other financial assets amount to $470.6 million1 (€425.9 million) as of December 31, 2023. Addition of proceeds from the public offering in January 2024 results in projected cash runway into 2027 Houston, Texas and Tuebingen, Germany, March 21, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2023. “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. “We are striving to reach multiple relevant milestones this year, including announcing clinical proof-of-concept for our half-life extended TCR Bispecifics platform. In parallel, the clinical data for our PRAME cell therapy, IMA203 GEN1, in conjunction with highly constructive FDA discussions, reinforces our confidence in advancing this asset toward a registration-enabling Phase 2/3 clinical trial in melanoma, while laying the groundwork to transition into a fully equipped commercial-stage company.” Full Year 2023 and Subsequent Company Progress ACTengine® IMA203 (PRAME) Clinical development plan update for ACTengine® IMA203 GEN1 and IMA203CD8 GEN2 monotherapies Following an RMAT designation in October 2023 and productive interactions with the FDA, Immatics plans to initiate a registration-enabling randomized Phase 2/3 trial in 2024 for IMA203 GEN1 in patients with second-line or later (2L+) cutaneous melanoma, potentially including also uveal melanoma patients. Immatics intends to assess IMA203 GEN1 targeting PRAME in HLA-A*02:01-positive cutaneous melanoma patients versus a control arm. This single trial will be designed to support accelerated approval based on an interim readout and full approval based on overall survival. The high prevalence of PRAME (≥95%) in cutaneous melanoma may enable the company to enroll patients without PRAME pre-testing. This would enhance trial operations and could remove the need to develop a companion diagnostic in this indication. The full trial design is currently being developed and is subject to further alignment with the FDA as part of the ongoing discussions. The Phase 2/3 trial is planned to start in 2024. For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development. In addition to treating melanoma patients, Immatics has also started to expand its clinical footprint outside of melanoma to address a broader patient population with a particular focus on ovarian and uterine cancers. A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024. Manufacturing capabilities Immatics’ late-stage clinical cell therapy development is supported by its streamlined manufacturing timeline, capabilities and facility. IMA203 GEN1 and IMA203CD8 GEN2 cell therapy products are manufactured within 7 days followed by a 7-day QC release testing at a success rate of >95% to reach the target dose (IMA203 GEN1: RP2D; IMA203CD8: DL4a). The company has also recently completed construction of a ~100,000 square foot R&D and GMP manufacturing facility with a modular design for efficient and cost-effective scalability to serve early-stage and registration-enabling clinical trials, as well as potential initial commercial supply. Interim clinical data update on ACTengine® IMA203 GEN1 and IMA203CD8 GEN2 monotherapies, as of November 2023 On November 8, 2023, Immatics provided an interim clinical update from the ongoing Phase 1 trial with ACTengine® IMA203 targeting PRAME in patients with recurrent and/or refractory solid cancers (data cut-off September 30, 2023). The update was focused on IMA203 GEN1 in melanoma patients at the recommended Phase 2 dose (RP2D, 1.0-10x109 total TCR-T cells) and the first clinical data for IMA203CD8 GEN2. Treatment with IMA203 GEN1 monotherapy (consisting of PRAME-specific functional CD8+ cells) in Phase 1a and Phase 1b Cohort A at RP2D demonstrated durable objective responses in melanoma patients with one patient exceeding 12 months and two patients exceeding 15 months post infusion and a 50% (6/12) confirmed objective response rate (cORR). Median duration of response (mDOR) was not reached (min 2.2+ months, max 14.7+ months) at a median follow-up (mFU) of 14.4 months. In line with previous results, IMA203 GEN1 monotherapy was well tolerated at total doses of up to 10x109 TCR-T cells infused. In addition, the first data on the company’s second-generation product candidate IMA203CD8 (consisting of PRAME-specific functional CD8+ and CD4+ cells) demonstrated 56% (5/9) cORR with enhanced pharmacology compared to IMA203 GEN1. mDOR was not reached (min 2.0+ months, max 11.5+ months) at a mFU of 4.8 months. As of the reported cut-off date, IMA203CD8 GEN2 exhibited a manageable tolerability profile. TCR Bispecifics Programs Immatics’ T cell engaging receptor (TCER®) candidates are next-generation, half-life extended TCR Bispecific molecules. They are designed to achieve a patient-convenient dosing schedule and to maximize efficacy while minimizing toxicities in patients through the proprietary format using a high-affinity TCR domain against the tumor target and a low-affinity T cell recruiter binding to the T cell. Upcoming milestones for Immatics’ clinical TCER® pipeline Immatics seeks to deliver clinical proof-of-concept for its novel TCER® platform as quickly as possible and plans to provide first clinical data for IMA401 (MAGEA4/8) and IMA402 (PRAME) in 2H 2024. Key objectives include: Demonstrating tolerability of the novel, next-generation, half-life extended TCR Bispecifics format;Optimizing dosing schedule to a less frequent regimen already during dose escalation, based on pharmacokinetics data; Demonstrating initial clinical anti-tumor activity (i.e., confirmed objective responses according to RECIST 1.1).TCER® IMA401 (MAGEA4/8) – The Phase 1 trial to evaluate safety, tolerability and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors is ongoing. IMA401 targets an HLA-A*02:01-presented peptide that occurs identically in two different proteins, MAGEA4 and MAGEA8. This target peptide has been selected based on natural expression in native solid tumors at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®). MAGEA4 and MAGEA8 are expressed in multiple solid cancers including lung cancer, head and neck cancer, melanoma, ovarian cancer, sarcoma and others. IMA401 is being developed in collaboration with Bristol Myers Squibb. First clinical data in at least 25 patients in dose escalation across multiple solid cancers is expected to be announced in 2H 2024.TCER® IMA402 (PRAME) – Immatics initiated the Phase 1/2 trial investigating the company’s fully owned TCER® candidate IMA402 in patients with recurrent and/or refractory solid tumors in August 2023 and the first patients have been dosed. Initial focus indications are ovarian cancer, lung cancer, uterine cancer, and cutaneous and uveal melanoma, among others. IMA402 targets an HLA-A*02:01-presented peptide derived from the tumor antigen PRAME. This target peptide has been selected based on natural expression in native solid primary tumors and metastases at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®). Immatics has recently engaged with a CDMO for the manufacturing of clinical IMA402 batches for its use within a potential registration-enabling trial. Patient recruitment and dose escalation continue to scale. First clinical data in at least 15 patients in dose escalation across multiple solid cancers, but initially focused on melanoma, is anticipated to be announced in 2H 2024. Corporate Development On January 22, 2024, Immatics completed an offering of 18,313,750 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, were approximately $201.5 million.In January 2024, Immatics hired Jason Braun as Senior Vice President Commercial to support the company as it transitions into a fully equipped commercial-stage entity and targets the initiation of a registration-enabling Phase 2/3 trial for its PRAME TCR-T cell therapy. Jason Braun joins the company with more than 20 years of experience in the biotech and pharma industry, having worked with several biopharmaceutical companies including Amgen, Dendreon, Pharmacyclics (Abbvie), Kite (Gilead) and Nkarta, among others. During his career, he has established a successful track record in the commercialization of oncology drug candidates. On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology. The collaboration spans various therapeutic modalities including bispecifics, cell therapy and cancer vaccines. Under the terms of the agreement, Immatics received an upfront payment of $120 million. In addition, Immatics will receive research funding and is eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.On July 24, 2023, Bristol Myers Squibb made a $35 million equity investment in Immatics, purchasing 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.46.In May 2023, Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate. As part of the agreement, Immatics received an option payment of $15 million and is eligible for up to $490 million in milestone payments in addition to tiered royalties on net sales of the product. Full Year 2023 Financial Results Cash Position: Cash and cash equivalents as well as other financial assets total €425.9 million ($470.6 million1) as of December 31, 2023, compared to €362.2 million ($400.2 million1) as of December 31, 2022. The increase is mainly due to upfront payments for collaborations, partly offset by our ongoing research and development activities. This does not include the net proceeds received in January 2024 from the public offering. Adding these proceeds, the company currently projects a cash runway into 2027. Revenue: Total revenue, consisting of revenue from collaboration agreements, was €54.0 million ($59.7 million1) for the year ended December 31, 2023, compared to €172.8 million ($190.9 million1) for the year ended December 31, 2022. The decrease is mainly the result of a one-time revenue for the license portion of the IMA401 collaboration with Bristol Myers Squibb for the year ended December 31, 2022. Research and Development Expenses: R&D expenses were €118.7 million ($131.2 million1) for the year ended December 31, 2023, compared to €106.8 million ($118.0 million1) for the year ended December 31, 2022. The increase mainly resulted from costs associated with the advancement of the clinical pipeline of ACTengine® and TCER® candidates.General and Administrative Expenses: G&A expenses were €38.2 million ($42.2 million1) for the year ended December 31, 2023, compared to €36.1 million ($39.9 million1) for the year ended December 31, 2022. Net Profit and Loss: Net loss was €97.0 million ($107.2 million1) for the year ended December 31, 2023, compared to a net profit of €37.5 million ($41.4 million1) for the year ended December 31, 2022. The decrease of net profit resulted mainly from the one-time license fee income in connection with the IMA401 collaboration with Bristol Myers Squibb, as well as the recognition of remaining deferred revenue in connection with the termination of the GSK collaboration for the year ended December 31, 2022. Full financial statements can be found in the Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) and published on the SEC website under www.sec.gov. Upcoming Investor Conferences Bank of America Health Care Conference, Las Vegas (NV) – May 14 - 16, 2024Jefferies Global Healthcare Conference, New York (NY) – June 5 - 7, 2024 To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations. - END - About ImmaticsImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn. Forward-Looking StatementsCertain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing and outcome of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND or CTA filing for pre-clinical stage product candidates, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable, Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification. For more information, please contact: Media
Trophic Communications
Phone: +49 171 3512733
immatics@trophic.eu
Immatics N.V.
Sabrina Schecher, Ph.D.
Senior Director, Investor Relations
Phone: +1 346 319-3325
InvestorRelations@immatics.com
Immatics N.V. and subsidiariesCondensed Consolidated Statement of Profit/(Loss) of Immatics N.V.
Year ended December 31,
2023
2022
2021
(Euros in thousands, except pershare data) Revenue from collaboration agreements
53,997 172,831 34,763 Research and development expenses
(118,663) (106,779) (87,574) General and administrative expenses
(38,198) (36,124) (33,808) Other income
1,13926 325
Operating result
(101,725) 29,954 (86,294) Change in fair value of liabilities for warrants
(2,079) 10,945 (10,990) Other financial income
13,850 9,416 5,675 Other financial expenses
(7,040) (8,279) (1,726)
Financial result
4,73112,082 (7,041)
Profit/(loss) before taxes
(96,994) 42,036 (93,335) Taxes on income
— (4,522)
— Net profit/(loss)
(96,994) 37,514 (93,335) Net profit/(loss) per share:
Basic
(1.20)0.56 (1.48) Diluted
(1.20) 0.55 (1.48) Immatics N.V. and subsidiariesCondensed Consolidated Statement of Comprehensive Loss of Immatics N.V.
Year ended December 31,
2023
2022
2021
(Euros in thousands) Net profit/(loss)
(96,994) 37,514 (93,335) Other comprehensive income/(loss)
Items that may be reclassified subsequently to profit or loss
Currency translation differences from foreign operations
(155) 2,464 3,514
Total comprehensive income/(loss) for the year
(97,149) 39,978 (89,821) Immatics N.V. and subsidiariesCondensed Consolidated Statement of Financial Position of Immatics N.V.
As of
December 31, 2023
December 31, 2022
(Euros in thousands) Assets
Current assets
Cash and cash equivalents
218,472 148,519 Other financial assets
207,423 213,686 Accounts receivables
4,093 1,111 Other current assets
19,382 13,838
Total current assets
449,370 377,154 Non-current assets
Property, plant and equipment
43,747 13,456 Intangible assets
1,523 1,632 Right-of-use assets
13,308 13,033 Other non-current assets
2,017 2,545
Total non-current assets
60,595 30,666
Total assets
509,965 407,820
Liabilities and shareholders’ equity
Current liabilities
Accounts payables
25,206 13,056 Deferred revenue
100,401 64,957 Liabilities for warrants
18,993 16,914 Lease liabilities
2,604 2,159 Other current liabilities
9,348 9,366
Total current liabilities
156,552 106,452 Non-current liabilities
Deferred revenue
115,527 75,759 Lease liabilities
12,798 12,403 Other non-current liabilities
4 42
Total non-current liabilities
128,329 88,204 Shareholders’ equity
Share capital
847 767 Share premium
823,166 714,177 Accumulated deficit
(597,293) (500,299) Other reserves
(1,636) (1,481)
Total shareholders’ equity
225,084 213,164
Total liabilities and shareholders’ equity
509,965 407,820
Immatics N.V. and subsidiariesCondensed Consolidated Statement of Cash Flows of Immatics N.V.
Year ended December 31,
2023
2022
2021
(Euros in thousands) Cash flows from operating activities
Net profit/(loss)
(96,994) 37,514 (93,335) Taxes on income— 4,522 —
Profit/(loss) before tax
(96,994) 42,036 (93,335) Adjustments for:
Interest income
(13,845)(2,476) (133) Depreciation and amortization
7,234 6,9675,260 Interest expenses
831 1,038566 Equity-settled share-based payment
20,70522,570 26,403 Net foreign exchange differences and expected credit losses
6,861 2,953(2,408) Change in fair value of liabilities for warrants
2,079(10,945)10,990 (Gains)/losses from disposal of fixed assets (150) — —
Changes in:
(Increase)/decrease in accounts receivables
(2,982) (429) 569 Decrease/(Increase) in other assets
(1,387) (7,872) (483) Increase/(decrease) in deferred revenue, accounts payables and other liabilities
85,99945,559(31,784) Interest received
10,167 1,649 175 Interest paid
(290)(695) (566) Income tax paid— (224) —
Net cash provided by/(used in) operating activities
18,228 100,131 (84,746)
Cash flows from investing activities
Payments for property, plant and equipment
(30,799) (5,738) (5,106 ) Payments for intangible assets
(158) (477) (551) Proceeds from disposal of property, plant and equipment
150 52 — Payments for investments classified in Other financial assets
(415,325) (216,323)(11,298) Proceeds from maturity of investments classified in Other financial assets
414,744 12,695 24,448
Net cash (used in)/provided by investing activities
(31,388) (209,791) 7,493
Cash flows from financing activities
Proceeds from issuance of shares to equity holders
90,404 134,484 94 Transaction costs deducted from equity
(2,039) (7,931) — Repayment of lease liabilities
(3,849)(2,843)(2,707)
Net cash provided by/(used in) financing activities
84,516 123,710 (2,613)
Net increase/(decrease) in cash and cash equivalents
71,356 14,050 (79,866)
Cash and cash equivalents at beginning of the year
148,519 132,994 207,530
Effects of exchange rate changes and expected credit losses on cash and cash equivalents
(1,403)1,475 5,330
Cash and cash equivalents at end of the year
218,472 148,519 132,994
Immatics N.V. and subsidiariesCondensed Consolidated Statement of Changes in Shareholders’ equity (deficit) of Immatics N.V.
(Euros in thousands)
Sharecapital
Sharepremium
Accumulateddeficit
Otherreserves
Totalshare-holders’equity
Balance as of January 1, 2021
629 538,695 (444,478) (7,459) 87,387 Other comprehensive income
— —
— 3,514 3,514 Net loss
—— (93,335) — (93,335) Comprehensive loss for the year
— — (93,335) 3,514 (89,821) Equity-settled share-based compensation
— 26,403 — — 26,403 Share options exercised
— 94 — — 94
Balance as of December 31, 2021
629 565,192 (537,813) (3,945) 24,063
Balance as of January 1, 2022
629 565,192 (537,813) (3,945) 24,063 Other comprehensive income
— — — 2,464 2,464 Net profit
— —37,514 — 37,514 Comprehensive income for the year
— — 37,514 2,464 39,978 Equity-settled share-based compensation
— 22,570 — — 22,570 Share options exercised
—
311 — — 311 Issue of share capital – net of transaction costs
138 126,104 — — 126,242
Balance as of December 31, 2022
767714,177 (500,299) (1,481) 213,164
Balance as of January 1, 2023
767 714,177 (500,299) (1,481) 213,164 Other comprehensive loss
— — — (155) (155) Net loss
— — (96,994) — (96,994) Comprehensive loss for the year
— — (96,994) (155) (97,149) Equity-settled share-based compensation
— 20,705 — — 20,705 Share options exercised
— 139 — — 139 Issue of share capital – net of transaction costs
80 88,145 — — 88,225
Balance as of December 31, 2023
847 823,166 (597,293) (1,636) 225,084
1 All amounts translated using the exchange rate published by the European Central Bank in effect as of December 31, 2023 (1 EUR = 1.105 USD).
Attachment
PDF Version
